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Allergic contact dermatitis: a case series and review
for the ophthalmologist
Sharon Morris,1 Richard Barlow,2 Dinesh Selva,3 Raman Malhotra1
ABSTRACT
Eyelid dermatitis is most commonly caused by an
allergenic response, potentially from exposure at another
site, rather than from local toxicity. Yet allergic contact
dermatitis is a diagnosis often missed by
ophthalmologists. The authors review the literature and
detail their experience relating to the causes, clinical
features and management of this condition. 14 patients
over a 2-year period that were referred to the oculoplastic
service for a further opinion were reviewed in
a retrospective, non-comparative study. All patients
underwent patch testing for diagnosis. 8 of the 14 patients
had delays of more than 6 months from symptoms to
diagnosis. In six of these, this was greater than 1 year.
Similar delays are reported in the literature. 79% of the
cases were referred by ophthalmologists. Although two of
the patients were biopsied, this did not help in making the
diagnosis. 13 patients had disease restricted to the
eyelids, though only five of these had direct contact of the
allergen with the eyelids. Two patients were also
sensitised to topical steroid creams prescribed for their
treatment. All patients improved after removal of the
allergen. Further clinical features and management
options from the literature are reviewed and discussed.
INTRODUCTION
Causes of an itchy, red eyelid include eczema and
psoriasis, seborrhoeic dermatitis, meibomitis/
blepharitis and rosacea, dermatomyositis, infec-
tions, infestations and malignancy.
Allergic contact dermatitis (ACD) is the
commonest cause of eyelid dermatitis.1e4 5 While
many patients never get to the stage of being
referred to an ophthalmologist, up to 13% of all
patients with ACD have been reported to present
with eyelid involvement.1e3 This may be the only
affected site and may result in delayed diagnosis.4 6
Eyelid inﬂammation tends to be attributed
by ophthalmologists more typically, and poten-
tially incorrectly, to local causes, such as topical
medications and eye-drops.
Eczema may result from exogenous/endogenous
factors. Contact dermatitis is due to exogenous
factors and can be irritant or allergic. Irritant
contact dermatitis, such as toxic reactions to eye-
drops, is caused by direct damage and penetration
of the skin, and represents only approximately 15%
of patients with persistent eyelid features.2 3 On
the other hand, ACD is a delayed type IV hyper-
sensitivity reaction to a speciﬁc allergen and
accounts for the majority.2 3 5 7 8 Atopic eczema,
which is endogenous, represents only 11e39%.2 3 9
While this is well described in the dermatological
literature, we believe that ophthalmologists are less
aware of the periorbital manifestations and
management of this condition. This descriptive
study of 14 patients referred to our oculoplastic
units for a second/third opinion highlights this
delay to diagnosis incurred prior to referral. In
addition, we review the current literature and detail
the important features of ACD.
MATERIALS AND METHODS
A retrospective non-comparative case series was
performed of patients referred between September
2006 and September 2008 to two specialist oculo-
plastic centres. Fourteen consecutive patients with
patch test proven allergens from two independent
units were included. The causes, clinical features,
management and outcome are described in relation
to these patients.
An up-to-date appraised review of the literature
was performed, including research from the Ovid
Medline and Embase databases. International
papers were incorporated. Review articles, large
case series and randomised controlled trials were
included after appraisal by two separate authors.
The main outcome measure was evidence-based
literature with clinical relevance.
RESULTS
We studied 14 patients (10 female, age range
5e72 years). Eleven patients were referred by an
ophthalmologist for a second opinion and the
remainder by their general practitioners. Clinical
details of each patient are included in table 1. All
patients presented with bilateral upper and lower
eyelid involvement, with one exception (Case 10)
that had unilateral disease secondary to an eyebrow
ring. Most complained of sore, itchy eyelids with
swelling of the skin. Some showed licheniﬁcation,
and in two patients (Cases 2 and 6) post-inﬂam-
matory hyperpigmentation was the most striking
feature (see ﬁgures 1AeF, 2A,B).
The duration of symptoms varied from 2 weeks
to 4.5 years (median 1 year, mean 13 months). Eight
patients had had symptoms for 6 months or more,
of whom ﬁve gave a history longer than a year.
Many had tried topical emollients and steroids, but
it was only upon withdrawal of the allergen that
their disease improved. All of our patients were
referred to a dermatologist for patch testing.
Two important features of our patients are the
range and type of allergens involved. These
included: quarternium-15, a constituent of
shampoo; nail polish resin; nickel; fragrance mix;
balsam of Peru; benzaklonium chloride 0.1% in
lubricant eye-drops; house dust mite; tixocortol




2St John’s Institute of
Dermatology, St Thomas’
Hospital, London, UK
3Discipline of Ophthalmology &
Visual Sciences, University of





Unit, Queen Victoria Hospital,
Holtye Road, East Grinstead
RH19 3DZ, UK; raman.
malhotra@qvh.nhs.uk
Accepted 9 September 2010
Published Online First
20 October 2010
Br J Ophthalmol 2011;95:903e908. doi:10.1136/bjo.2009.174607 903
Review
 group.bmj.com on June 3, 2012 - Published by bjo.bmj.comDownloaded from 
hydrocortisone, Eumovate, Betnovate and Dermovate creams;
and an excipient in Eumovate cream.
DISCUSSION
Eyelid dermatitis is not uncommon, with one author9 reporting
involvement in as many as 10% of all general dermatology
outpatients. The differential diagnosis includes contact and atopic
eczema, seborrhoeic dermatitis, blepharitis, rosacea, psoriasis,
dermatomyositis, impetigo and cutaneous Tcell lymphoma.
Acute ACD may present with erythema and macules, papules
and/or vesicles. However, blisters are rare on the eyelids.
Licheniﬁcation, scaling and ﬁssuring are features of more chronic
disease. The incidence of ACD as a cause of eyelid dermatitis
varies from 29 to 77% of patients reported,1e3 5 7 8 10 and
has been found to be the most likely cause if all four eyelids are
involved.10 It is more common in middle-aged patients with
less pigmented skin. Amin et al11 reported 85.4% of their
patients with ACD as Caucasian in origin with the greatest
prevalence in the 41e70-year-old age range. Females are most
frequently affected (61.8e90% of patients) because of the use of
cosmetics.1 2 5 7 8 10
Immune process
Two stages are necessary in the development of ACDdan initial
immune-mediated sensitisation to the allergen and then






diagnosis Patch testing positive results Management Outcome
1 46 Sore, itchy upper and lower
eyelids with erythematous scaling
and thickening medially in butterfly
pattern. No benefit with steroid/
antifungal creams/emollients.










Reducing regime of Betnovate
ointment daily for 2 days,
Betnovate RD daily for 3 days,
then 1% hydrocortisone daily.
Dramatic improvement
within 1 month
2 20 Bilateral periocular dermatitis
with cicatricial medial ectropion.
Inner canthal skin lichenification.
No resolution with steroid ointments
or moisturisers to the skin.





3 74 Itchy eczematous dermatitis of
eyelids, mild eczematous changes
to cheeks and behind ear
9 months Caine mix, fragrance mix, nickel
and carba mix, E45 itch relief cream,
Eumovate (no reaction to Diprobase/
hydrocortisone)
Avoidance of allergens,
Diprobase ointment to wash
and moisturise three times a day,
hydrocortisone ointment
0.5e2.5% depending on redness
Clinically much improved
within 2 months
4 45 Bilateral, itchy, asymmetrical
erythematous eyelids. No other
dermatitis elsewhere on body/
face except periungual vesicles
on fingers.
2 months Nail polish; toluene-sulfonamide
formaldehyde resin
Changed to ‘hypoallergenic’
polyester resin nail polish, 1%
hydrocortisone ointment three
times a day to eyelids
Complete resolution within
2 weeks
5 72 Mild intermittent erythema
and eczematous eyelid changes.
1 year Apitol, chloroethylene and ethylene
diamine
Stopped mascara wear. No
response to Elidel 1% or




6 50 Episodic eyelid rashes, puffiness
and skin darkness.
1 year Nickel, fragrance, balsam of Peru
and imidazolidinyl urea preservative
Avoidance of allergens. Complete resolution
7 49 Eyelid puffiness, episodic itchy
erythematous eyelid skin.
Occasional neck rash.
3 years Methylchloroisothiazolinone and
methlisothiazolinone, from shampoo
and her Cre`me de la Mere foundation
Avoidance of products Improved within
2 months
8 56 Bilateral periocular dermatitis,
itchy lids with some lichenification
4 months Fragrance mix Ceased aftershave lotion,
hydrocortisone 1% ointment
three times a day to eyelids
Resolved within
4 weeks
9 61 Periocular dermatitis and bilateral
conjunctival inflammation since
starting ocular lubricants
2 weeks Benzalkonium chloride 0.1% aq Topical lubricants stopped,
predsol 0.5% four times a day
both eyes and topical hydrocortisone
1% three times a day to eyelid skin
2 week resolution
10 23 Left-sided eyelid and eyebrow
dermatitis, following insertion of
eyebrow ring




11 5 Bilateral lichenified itchy eyelids 6 months House dust mite Measures to decrease exposure
(mattress/pillow protectors, cleaning
of floors, open windows daytime,
washing stuffed toys etc). Topical




12 52 Bilateral upper and lower eyelid
erythema and oedema. Failed
treatment with hydrocortisone 1%
ointment.




Avoidance of allergens Full resolution within
2 months
13 50 Bilateral upper lid erythemadreferred
for consideration of blepharoplasties
6 months Parabens and lanolin Avoidance of face creams.
Reducing regime of hydrocortisone
1% ointment.
Complete resolution
14 28 Sore, itchy, erythematous upper and
lower eyelids
1 year Nickel sulfate Avoidance of her eyelash curlers.
No topical creams necessary.
Complete resolution
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elicitation of the inﬂammatory response. Sensitisation involves
penetration of an allergen through the skin and binding to
Langerhans antigen-presenting cells. These cells migrate to the
lymph nodes and sensitise naïve T lymphocytes, which then
relocate themselves back in the skin but throughout the skin.
The inﬂammatory response is elicited by re-exposure to the
allergen.
Most environmental allergens are haptensdsimple <500 Da
electrophilic molecules that must link to proteins to form
a complete antigen before they can sensitise.12 There are more
than 2800 known environmental allergens,13 but not all are
haptens. If the hapten complexes with a non-immunogenic
carrier, then tolerance is induced, rather than sensitisation.14 The
carriers for contact allergens are HLA-DR or class II antigens on
the surface of the Langerhan cells.15
Because ACD is immune-mediated, compromised immunity is
associated with decreased reactivity or anergy. The ageing
process modulates ACD, possibly due to a decrease in density
of antigen presenting cells and production of proinﬂammatory
cytokines.16 In addition, children and infants can be affected
by ACD. It is unclear when immunocompentence is achieved,
but patch testing has been performed in infants younger than
2 years of age.17 More typically, ACD is seen in older children.
Investigation
Skin biopsies are unlikely to distinguish between ACD and other
forms of eczema but may help to exclude impetigo and
lymphoma. Irritant and ACD both show spongiosis and
a lymphocyte inﬁltrate. Acute irritant contact eczema usually
shows more ballooning degeneration and necrotic keratocytes,
whereas ACD shows more spongiosis of the epidermis.18
Patch testing is the key investigation used to identify
allergens. Frequent contact allergens in eyelid ACD are shown in
table 2. Eyelids are particularly susceptible to ACD because the
skin is thinner (thickness of 0.55 mm) than on the rest of the
face (2.0 mm thick). This allows easier penetration of
the allergen than at other sites, and eyelid dermatitis may
therefore be the only manifestation.11 In addition, eyelids may
manifest a reaction without direct contact of the allergen at this
site.
A thorough history should be taken to identify possible
allergens. Details of cosmetics, hobbies and occupation may be
relevant. The eyes, eyelids, face and hands (including nails)
should be carefully examined.
Patch testing involves application of allergens under Finn
Chambers to the patient’s back. Reactions are read at varying
intervals. Standard batteries of patch tests, for example Euro-
pean standard series, TRUE test and North American CD Group
series,19 do not include every relevant eyelid allergen, and the
test should be adjusted for each patient. Guin found that 66 out
of a total of 167 patients with ACD would have remained
undiagnosed if the TRUE test was used alone.9 Similarly, Katz
and Sherertz4 found that the TRUE test alone would have
detected only 37% of ACD allergens, and the North American
Figure 1 (AeC) Images corresponding to Case 4 in the series who was found to be allergic to her nail polish. Note the bimedial upper and lower lid
erythema and thickening. Examination of her fingernails revealed periungual vesiculation (C). (D, E) Another patient from our case series with the
typical bimedial upper and lower lid erythema in a ‘butterfly’ distribution. (F) Histology specimen from the same patient (H&E stain,310 magnification).
Lichenification, hyperkeratinisation, non-specific generalised inflammatory cell infiltate and a thickened cornea stratum are seen.
Figure 2 (A) Patient referred by an
ophthalmologist for upper
blepharoplasties. Allergic contact
dermatitis was found to be causative.
Bilateral upper lid erythema is clearly
visible in this photo. (B) Patient
demonstrating subtle features of eyelid
‘eczematous’ dermatitis and medial lower lid ectropion. This clinical appearance had prompted repeated prescriptions of steroid cream treatment prior
to his presentation to our unit. He was found to be patch-test-positive to Eumovate cream.
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CD Group only 42% of allergens. The most common relevant
allergens are the patient’s own personal care products.
While patch testing often provides the answer for the patient,
interpretation should be performed by an experienced clinician.
Untrained interpretation exposes the patient to incorrect over-
and undertesting, deceptive results and potentially unwanted
sensitisation. Interpretation involves being able to separate irri-
tant and allergic reactions, determining the relevance of the
antigen, and the optimum reading time and appreciation of
cross-reactions and coreactivity.
False positives can occur if the allergen causes an irritant
rather than allergic response. The test may need to be repeated
with the allergen at a lower concentration. In addition, even if
a chemical is found to be allergenic, it cannot be assumed that it
is causative. The relevance of the antigen is important. A
provocation test or repeat open application testing may be
necessary. This involves the patient applying the commercial
product to their skin several times daily for 1e2 weeks.20
Most false-negative responses can be avoided by performing
a second reading of the test sites 48 h after the ﬁrst. Some
studies advocate readings at 4e7 days, especially in older
patients, to ensure any allergic response is elicited.21 22
Neomycin reactions may take longer: one study showed that
half are not evident until 96 h.23 In addition, if too low
a concentration is used in testing, sensitisation may not occur.
Sensitisation is dependent on the dose of chemical per unit area
of skin (up to a limit of 0.1 cm2).24 Concentrations of
ophthalmic preparations may need to be tested at a higher level
owing to difﬁculty in penetrating the skin on the back.25
Side effects of patch testing include a severe local reaction or
ﬂare reaction at a distant site, an ‘angry back/excited skin’
syndrome where numerous positive reaction occur, pigment
changes, scarring and keloids, infections and potentially
anaphylaxis. 26 For all of these reasons, patch testing should be
performed by an experienced dermatologist.
Treatment
It is well established that patients may occasionally continue to
have symptoms even after avoidance of the allergen.27 28
Treatment for symptom relief is therefore required in addition to
simply identifying responsible allergens.
Treatment should include emollients, treatment of secondary
infection if present and downregulation of the immune
response. Topical antipruritics should be avoided because of the
risk of secondary sensitisation.29
Glucocorticosteroids are usually the primary choice for
immune modulation, and their effective treatment of ACD is
well documented.30e32 Inﬂammation is reduced by suppressing
the recruitment of polymorphonuclear leucocytes and reversing
capillary permeability. Topical steroids are usually sufﬁcient, and
treatment should be limited to 2e3 weeks’ duration. Low-
potency steroids such as hydrocortisone and desonide are safer
for use on the face, though stronger steroids such as clobetasone
proprionate or betamethasone diproprionate are used for
moderate to severe disease.33 Longstanding application of topical
steroids is associated with skin atrophy, telangiectases and
acneiform reactions. If more than 20% of the body surface area is
involved, or if there are bullae or extensive facial involvement,
then treatment should be considered with systemic steroids.
It is important to be aware that topical steroids may them-
selves be allergenic, as seen in case 12. One study34 of 31 patients
with ACD who had worsened or had shown no response to
topical corticosteroid treatment found that 22% had a positive
patch test result to the steroid itself. In other studies,35 36 the
steroid has been implicated in 0.2e5%.
Ascomyscins such as tacrolimus (TK506) (Protopic oinment
0.03% or 0.1%) and pimecrolimus (ASM 981) (Elidel cream) have
recently been introduced as treatment options and provide
a solution for thin-skin areas, for example the face and eyelids.37 38
They are topical calcineurin inhibitors and cause a reduction
in interleukin, leucotriene, histamine and serotonin release,
thereby effectively suppressing the immune response.29 39
Both agents target the human epidermal Langerhans cell40 and
have been shown to inhibit the elicitation phase of ACD in
a mouse model.41 In addition, a study in humans found that
tacrolimus also suppresses the sensitisation phase.42 Tacro-
limus ointment at concentrations of both 0.03% and 0.1% has
been found to be an effective treatment for nickel-induced
steroid resistant ACD in adult and paediatric patients. Safety
and efﬁcacy of usage has also been reported in children aged
2 years or older.12 A 0.1% concentration is probably more
effective43e45 but is more frequently a cause of itching and
burning. These rapidly decrease after the ﬁrst week of treat-
ment. Although Ciclosporin A is also a successful calcineurin
inhibitor, it has limited penetration through the epidermis and
limited topical application for this condition.30 46 47
Ascomycins have been compared with topical steroids. A
small double-blind RCT pilot study48 examining nickel ACD
looked at four treatment groupsdpimecrolimus 1% cream,
tacrolimus 0.1% ointment, clobetasol 0.05% ointment, triam-
cinolone 0.1% ointmentdand two control groups of topical
vehicle application. No statistically signiﬁcant differences were
found between any of the groups, although the treatment
groups showed a clear trend towards being more effective than
Table 2 Common contact allergens particularly relevant to eyelid
allergic contact dermatitis
Allergen Source
Gold sodium thiosulfate 0.5% Jewellery/metal
Fragrance and preservative Cosmetics, shampoos, soaps,
moisturisers, lotions
Nickel Jewellery, eyelash curlers, traces in
make-up
Thiuram mix Rubber of eyelash curlers
Cocamidopropyl betaine 1% (CAPB),
Amidoamine 0.1%, Quarternium-15 2%
Preservatives and surfactants in
shampoos
Tosylamide formaldehyde resin Fingernail polish, adhesives, glues,
bonding agents
Neomycin Topical medications
Benzalkonium chloride Topical medications, face washes, hand
scrubs, cosmetics
Dust mites or animal dander Make-up brushes
Table 3 Recommended four-step approach to management of
suspected allergic contact dermatitis
1 History Ask about known allergens, types of cosmetics, occupational
and leisure pursuits. Remember that allergens may not
necessarily be those in direct contact with the eye.
2 Examination Eyelids and nailsdmay not have localised nailbed changes.
Check for artificial nails.
3 Refer for patch
testing
Standard patch testing batteries should be supplemented with
patient’s own cosmetics or particular allergens from history.
Allow 48e96 h prior to result reading.
4 Treatment Cessation of allergen contact.
Symptom reliefdemollients, topical antipruritics, oral antihis-
tamines.
A 2e3 week course of topical steroids or tacrolimus/
pimecrolimus use.
906 Br J Ophthalmol 2011;95:903e908. doi:10.1136/bjo.2009.174607
Review
 group.bmj.com on June 3, 2012 - Published by bjo.bmj.comDownloaded from 
control. However, Saripalli et al49 induced nickel ACD in patients
and found that tacrolimus was signiﬁcantly more effective than
vehicle. Alomar et al50 corroborated this ﬁnding. Similarly,
pimecrolimus at 0.2% and 0.6% formulations has successfully
treated nickel-induced ACD.51
Other treatment options for more widespread disease away
from the eyes, patients who are unresponsive to the above
treatments or those who cannot avoid the provoking factors
include phototherapydultraviolet A photochemotherapy (oral
psoralen photochemotherapy) and shortwave UVB light. In
addition, use of Grenz rays52 and systemic immunosuppres-
sants53 such as azathioprine and mycophenolate mofatil have
been described in ACD.
In our study, all of the patients improved with removal of the
allergen with/without a short course of topical
immunosuppressants.
In conclusion, eyelid dermatitis may be the only dermato-
logical manifestation of ACD (see summary in table 3). A delay
in diagnosis commonly hinders appropriate treatment and
avoidance of allergens. In our experience, marked delays were
due to a lack of awareness of the condition by referring
ophthalmologists. Improved awareness is essential. In addition,
it should be remembered that the corticosteroids used to treat
ACD may in fact be causative themselves, and patients who are
unresponsive to treatment ought to have corticosteroids
included as potential allergens in their patch testing.
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